William L Carroll

List of Publications by Citations

349 papers	16,575 citations	65 h-index	125 g-index
357 ext. papers	19,294 ext. citations	4.8 avg, IF	5.86 L-index

#	Paper	IF	Citations
349	Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *New England Journal of Medicine*, **2009**, 360, 470-80	59.2	1030
348	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *New England Journal of Medicine*, **2014**, 371, 1005-15	59.2	885
347	Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *Journal of Clinical Oncology*, **2012**, 30, 1663-9	2.2	758
346	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*, **2008**, 111, 5477-85	2.2	621
345	Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. *Journal of Clinical Oncology*, **2009**, 27, 5175-81	2.2	540
344	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*, **2012**, 22, 153-66	24.3	515
343	Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. *Nature Genetics*, **2009**, 41, 1243-6	36.3	465
342	JAK mutations in high-risk childhood acute lymphoblastic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 9414-8	11.5	446
341	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nature Genetics*, **2017**, 49, 1211-1218	36.3	430
340	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*, **2010**, 115, 5312-21	2.2	425
339	Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nature Genetics*, **2009**, 41, 1001-5	36.3	383
338	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). *Blood*, **2007**, 109, 926-35	2.2	338
337	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. *Journal of Clinical Oncology*, **2016**, 34, 2380-8	2.2	219
336	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. *Blood*, **2015**, 126, 964-71	2.2	217
335	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 290-4	36.3	216
334	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. *Nature Communications*, **2015**, 6, 6604	17.4	215
333	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nature Genetics*, **2013**, 45, 1494-8	36.3	205

332	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. *Nature Genetics*, **2011**, 43, 237-41	36.3	201
331	Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. *Journal of Clinical Oncology*, **2008**, 26, 3756-62	2.2	193
330	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nature Genetics*, **2019**, 51, 296-307	36.3	189
329	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **2012**, 119, 3512-22	2.2	181
328	Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. *Journal of Clinical Oncology*, **2008**, 26, 3971-8	2.2	180
327	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2015**, 313, 815-23	27.4	179
326	Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2009**, 301, 393-403	27.4	174
325	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. *Blood*, **2017**, 129, 3352-3361	2.2	168
324	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. *Journal of the National Cancer Institute*, **2013**, 105, 733-42	9.7	167
323	Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. *Journal of Clinical Oncology*, **2010**, 28, 4755-61	2.2	163
322	Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. *Blood*, **2010**, 115, 1394-405	2.2	163
321	Mouse x human heterohybridomas as fusion partners with human B cell tumors. *Journal of Immunological Methods*, **1986**, 89, 61-72	2.5	161
320	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. *Blood*, **2008**, 112, 4178-83	2.2	157
319	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. *Blood*, **2011**, 118, 5218-26	2.2	155
318	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. *Blood*, **2013**, 121, 485-8	2.2	136
317	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Blood*, **2006**, 107, 4061-7	2.2	133
316	Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **2006**, 108, 711-7	2.2	133
315	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2012**, 30, 751-7	2.2	131

314	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. *Pediatric Blood and Cancer*, **2013**, 60, 957-63	3	121
313	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. *Journal of Clinical Oncology*, **2018**, 36, 2306-2314	2.2	119
312	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. *Blood*, **2018**, 131, 995-999	2.2	112
311	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. *Blood*, **2012**, 119, 5201-10	2.2	111
310	Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. *Pediatric Blood and Cancer*, **2006**, 47, 130-40	3	111
309	Hybridoma fusion cell lines contain an aberrant kappa transcript. *Molecular Immunology*, **1988**, 25, 991-5	4.3	111
308	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. *Blood*, **2018**, 131, 1350-1359	2.2	108
307	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*, **2011**, 118, 243-51	2.2	108
306	Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *Blood*, **2011**, 118, 6043-9	2.2	102
305	Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. *Journal of Clinical Oncology*, **2013**, 31, 3397-402	2.2	99
304	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. *Nature Genetics*, **2015**, 47, 607-14	36.3	96
303	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. *Journal of Clinical Oncology*, **2018**, 36, 2926-2934	2.2	95
302	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. *Blood*, **2014**, 123, 2017-25	2.2	93
301	Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. *Journal of Clinical Oncology*, **2008**, 26, 4376-84	2.2	89
300	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. *Blood*, **2015**, 126, 1770-6	2.2	86
299	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. *Journal of Clinical Oncology*, **2018**, 36, 591-599	2.2	85
298	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. *Blood*, **2015**, 125, 680-6	2.2	84
297	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *JAMA Oncology*, **2015**, 1, 287-95	13.4	84

296	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*, **2012**, 119, 1872-81	2.2	84
295	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. *Nature Medicine*, **2013**, 19, 1014-22	50.5	82
294	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. *Blood*, **2014**, 124, 1-1	2.2	80
293	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. *Pediatric Blood and Cancer*, **2015**, 62, 1171-5	3	79
292	A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Cancer*, **2014**, 120, 1417-25	6.4	79
291	Biology and treatment of acute lymphoblastic leukemia. *Pediatric Clinics of North America*, **2008**, 55, 1-20, ix	3.6	76
290	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. *Blood*, **2015**, 126, 2202-12	2.2	75
289	End points to establish the efficacy of new agents in the treatment of acute leukemia. *Blood*, **2007**, 109, 1810-6	2.2	74
288	Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. *ACS Chemical Biology* , **2016**, 11, 1305-12	4.9	71
287	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. *Blood*, **2014**, 124, 1266-76	2.2	70
286	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. *Journal of Clinical Oncology*, **2014**, 32, 3874-82	2.2	66
285	Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. *Blood*, **2012**, 119, 817-25	2.2	66
284	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. *Pediatric Blood and Cancer*, **2015**, 62, 1176-83	3	65
283	Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Journal of Clinical Oncology*, **2012**, 30, 2753-9	2.2	65
282	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. *Blood*, **2018**, 132, 815-824	2.2	58
281	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. *Blood*, **2011**, 117, 3010-5	2.2	58
280	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2016**, 34, 2133-40	2.2	57
279	Identification of gene expression profiles that segregate patients with childhood leukemia. *Clinical Cancer Research*, **2002**, 8, 3118-30	12.9	56

278	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. *Blood*, **2015**, 126, 69-75	2.2	54
277	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. *Journal of Clinical Oncology*, **2020**, 38, 602-612	2.2	52
276	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 3282-3293	2.2	51
275	Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. *British Journal of Haematology*, **2014**, 167, 87-99	4.5	50
274	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2020**, 38, 1897-1905	2.2	49
273	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. *Blood*, **2013**, 121, 148-55	2.2	48
272	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group. *Cancer*, **2016**, 122, 1116-25	6.4	47
271	Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. *Cancer*, **2016**, 122, 1608-17	6.4	46
270	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. *Journal of Clinical Oncology*, **2018**, 36, 10500-10500	2.2	46
269	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. *Pediatric Blood and Cancer*, **2011**, 57, 569-77	3	45
268	Experimental validation of simulation methods for bi-directional transmission properties at the daylighting performance level. *Energy and Buildings*, **2006**, 38, 878-889	7	45
267	Childhood bone marrow monosomy 7 syndrome: a familial disorder?. *Journal of Pediatrics*, **1985**, 107, 578-80	3.6	45
266	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (Ph-like or BCR-ABL1-Like) Signature For Therapeutic Targeting and Clinical Intervention. *Blood*, **2013**, 122, 826-826	2.2	45
265	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. *International Journal of Cancer*, **2016**, 138, 332-9	7.5	44
264	Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. *Journal of Biological Chemistry*, **2014**, 289, 20502-15	5.4	44
263	Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. *Cancer Cell*, **2020**, 37, 867-882.e12	24.3	43
262	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 2527-2534	2.2	43
261	Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada. *Environmental Health Perspectives*, **2007**, 115, 158-64	8.4	43

260	Expression of the c-Myc protein in childhood medulloblastoma. *Journal of Pediatric Hematology/Oncology*, **1998**, 20, 18-25	1.2	41
259	Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). *Pediatric Blood and Cancer*, **2015**, 62, 419-26	3	39
258	Clinical and laboratory biology of childhood acute lymphoblastic leukemia. *Journal of Pediatrics*, **2012**, 160, 10-8	3.6	38
257	The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. *American Journal of Pathology*, **2002**, 161, 875-83	5.8	37
256	Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. *Pediatric Blood and Cancer*, **2021**, 68, e28843	3	37
255	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. *Journal of Clinical Oncology*, **2019**, 37, 780-789	2.2	33
254	Childhood leukemia--new advances and challenges. *New England Journal of Medicine*, **2004**, 351, 601-3	59.2	33
253	Epigenetic deregulation in pediatric acute lymphoblastic leukemia. *Epigenetics*, **2014**, 9, 459-67	5.7	32
252	Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. *British Journal of Haematology*, **2012**, 157, 507-10	4.5	31
251	Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. *British Journal of Haematology*, **2019**, 186, 274-285	4.5	30
250	Childhood acute lymphoblastic leukemia in the age of genomics. *Pediatric Blood and Cancer*, **2006**, 46, 570-8	3	30
249	The molecular biology of pediatric lymphomas. *Journal of Pediatric Hematology/Oncology*, **1998**, 20, 282-96	1.2	30
248	Progress and Prospects in Pediatric Leukemia. *Current Problems in Pediatric and Adolescent Health Care*, **2016**, 46, 229-241	2.2	29
247	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). *Blood*, **2013**, 122, 3903-3903	2.2	29
246	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 414-8	3	28
245	The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, 413-8	1.2	28
244	Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. *Oncogene*, **1997**, 15, 1937-46	9.2	28
243	c-myc hypermutation in Burkitt's lymphoma. *Leukemia and Lymphoma*, **1992**, 8, 431-9	1.9	28

242	New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. *Expert Review of Anticancer Therapy*, **2017**, 17, 725-736	3.5	27
241	A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, 458-63	1.2	27
240	Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. *Pediatric Blood and Cancer*, **2012**, 59, 834-9	3	26
239	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). *Leukemia*, **2018**, 32, 1370-1379	10.7	25
238	Novel targeted drug therapies for the treatment of childhood acute leukemia. *Expert Review of Hematology*, **2009**, 2, 145	2.8	25
237	Development of the human antibody repertoire. *Pediatric Research*, **1992**, 32, 257-63	3.2	25
236	MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. *Haematologica*, **2018**, 103, 830-839	6.6	24
235	A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. *Oncotarget*, **2015**, 6, 16527-42	3.3	24
234	HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 2565-7	1.9	23
233	Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. *Leukemia*, **2018**, 32, 1393-1403	10.7	22
232	A novel intron element operates posttranscriptionally To regulate human N-myc expression. *Molecular and Cellular Biology*, **1999**, 19, 155-63	4.8	22
231	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. *Blood*, **2017**, 129, 1919-1926	2.2	21
230	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. *Cancer Genetics*, **2019**, 238, 62-68	2.3	21
229	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*, **2017**, 35, 2700-2707	2.2	20
228	Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. *Pediatric Blood and Cancer*, **2014**, 61, 1779-85	3	20
227	Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough?. *Pediatric Blood and Cancer*, **2005**, 45, 876-80	3	20
226	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. *Blood*, **2011**, 118, 573-573	2.2	19
225	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. *Leukemia and Lymphoma*, **2019**, 60, 1740-1748	1.9	18

224	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. *Cancer*, **2018**, 124, 1150-1159	6.4	18
223	Immune-Based Therapies in Acute Leukemia. *Trends in Cancer*, **2019**, 5, 604-618	12.5	18
222	Diversity of immunoglobulin light chain usage in the human immune response to Haemophilus influenzae type b capsular polysaccharide. *Pediatric Research*, **1993**, 33, 307-11	3.2	18
221	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. *Journal of Clinical Oncology*, **2017**, 35, 1730-1736	2.2	17
220	Gene expression profiling. Methods and clinical applications in oncology. *Hematology/Oncology Clinics of North America*, **2001**, 15, 911-30, ix	3.1	17
219	Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children Oncology Group (COG) Study AALL0031.. *Blood*, **2007**, 110, 4-4	2.2	17
218	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. *Pediatric Blood and Cancer*, **2010**, 54, 872-8	3	16
217	Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children Oncology Group (COG).. *Blood*, **2008**, 112, 898-898	2.2	16
216	Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. *Leukemia and Lymphoma*, **2016**, 57, 1938-41	1.9	15
215	Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2. *Cancer*, **2004**, 101, 2106-15	6.4	15
214	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children Oncology Group (COG) study.. *Journal of Clinical Oncology*, **2019**, 37, 10008-10008	2.2	15
213	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. *Cancer*, **2018**, 124, 571-579	6.4	15
212	Integrin mediates the drug resistance of acute lymphoblastic B-cell leukemia. *Blood*, **2020**, 136, 210-223	3.2	14
211	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction A Children's Oncology Group (COG) Study.. *Blood*, **2009**, 114, 9-9	2.2	14
210	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children Oncology Group (COG) Study AALL0331. *Blood*, **2014**, 124, 793-793	2.2	13
209	Race and outcome in childhood acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2003**, 290, 2061-3	27.4	12
208	Pancytopenia with myelofibrosis. An unusual presentation of childhood Hodgkin's disease. *Clinical Pediatrics*, **1986**, 25, 106-8	1.2	12
207	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. *Blood*, **2009**, 114, 704-704	2.2	12

206	Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. *Pediatric Blood and Cancer*, **2016**, 63, 255-61	3	12
205	Therapies on the horizon for childhood acute lymphoblastic leukemia. *Current Opinion in Pediatrics*, **2016**, 28, 12-8	3.2	12
204	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. *Haematologica*, **2019**, 104, 986-992	6.6	12
203	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. *Cancer Medicine*, **2018**, 7, 3-12	4.8	11
202	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. *Blood*, **2015**, 126, 794-794	2.2	11
201	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. *Haematologica*, **2021**, 106, 46-55	6.6	10
200	Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. *Clinical Cancer Research*, **2020**, 26, 256-264	12.9	10
199	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. *Journal of Clinical Oncology*, **2021**, 39, 1437-1447	2.2	10
198	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. *Journal of Clinical Oncology*, **2020**, 38, 2628-2638	2.2	9
197	Immunoglobulin variable region usage in human intestinal B lymphocytes. *Clinical Immunology and Immunopathology*, **1994**, 71, 240-5		9
196	Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children Oncology Group Study 1991. *Blood*, **2008**, 112, 9-9	2.2	9
195	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. *Blood*, **2011**, 118, 1510-1510	2.2	9
194	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children Oncology Group (COG) AALL0331. *Blood*, **2013**, 122, 837-837	2.2	9
193	Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. *Paediatric Drugs*, **2020**, 22, 485-499	4.2	9
192	Safety in numbers: hyperdiploidy and prognosis. *Blood*, **2013**, 121, 2374-6	2.2	8
191	Somatic hypermutation in T-independent and T-dependent immune responses to Haemophilus influenzae type b polysaccharide. *Clinical Immunology and Immunopathology*, **1998**, 89, 240-6		8
190	Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. *Apoptosis: an International Journal on Programmed Cell Death*, **2006**, 11, 1977-86	5.4	8
189	Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).. *Blood*, **2006**, 108, 146-146	2.2	8

188	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. *Blood Advances*, **2019**, 3, 1647-1656	7.8	8
187	Mechanisms of -Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia. *Molecular Cancer Therapeutics*, **2019**, 18, 1887-1895	6.1	8
186	NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. *Leukemia*, **2018**, 32, 2527-2535	10.7	8
185	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. *Haematologica*, **2019**, 104, e517-e520	6.6	7
184	Analysis of hypermutation in immunoglobulin heavy chain passenger transgenes. *European Journal of Immunology*, **1996**, 26, 1058-62	6.1	7
183	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children Oncology Group AALL0622.. *Journal of Clinical Oncology*, **2015**, 33, 10006-10006	2.2	7
182	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. *Blood*, **2018**, 132, 35-35	2.2	6
181	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. *Blood*, **2009**, 114, 1580-1580	2.2	6
180	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 232-232	2.2	6
179	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131. *Blood*, **2015**, 126, 1303-1303	2.2	6
178	Definition of the human N-myc promoter region during development in a transgenic mouse model. *Pediatric Research*, **1999**, 46, 255-62	3.2	6
177	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. *Journal of Pediatric Hematology/Oncology*, **2016**, 38, 409-17	1.2	6
176	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. *Leukemia*, **2021**, 35, 1279-1290	10.7	6
175	Beating the Clock in T-cell Acute Lymphoblastic Leukemia. *Clinical Cancer Research*, **2017**, 23, 873-875	12.9	5
174	Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia. *Paediatric Drugs*, **2007**, 9, 149-56	4.2	5
173	The absence of ongoing immunoglobulin gene hypermutation suggests a distinct mechanism for c-myc mutation in endemic Burkitt's lymphoma. *Journal of Pediatric Hematology/Oncology*, **1996**, 18, 29-35	1.2	5
172	Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia. *Blood*, **2008**, 112, 2925-2925	2.2	5
171	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 618-618	2.2	5

170	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434. *Blood*, **2014**, 124, 3649-3649	2.2	5
169	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group study AALL0232.. *Journal of Clinical Oncology*, **2012**, 30, CRA9508-CRA9508	2.2	5
168	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. *Leukemia*, **2020**, 34, 1006-1016	10.7	5
167	Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. *Journal of Pediatric Hematology/Oncology*, **2016**, 38, e21-5	1.2	5
166	Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia. *Pediatric Blood and Cancer*, **2020**, 67, e28306	3	4
165	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. *Molecular Cancer Research* , **2020**, 18, 1153-1165	6.6	4
164	Building better therapy for children with acute lymphoblastic leukemia. *Cancer Cell*, **2005**, 7, 289-91	24.3	4
163	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. *Blood*, **2019**, 134, 1293-1293	2.2	4
162	Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children's Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.. *Blood*, **2006**, 108, 1865-1865	2.2	4
161	Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children's Oncology Group (COG) Study.. *Blood*, **2006**, 108, 219-219	2.2	4
160	Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL.. *Blood*, **2006**, 108, 2272-2272	2.2	4
159	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study.. *Blood*, **2009**, 114, 3091-3091	2.2	4
158	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. *Blood*, **2009**, 114, 85-85	2.2	4
157	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. *Blood*, **2012**, 120, 137-137	2.2	4
156	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. *Blood*, **2013**, 122, 825-825	2.2	4
155	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. *Blood*, **2014**, 124, 684-684	2.2	4
154	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). *Blood*, **2015**, 126, 807-807	2.2	4
153	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children's Oncology Group study.. *Journal of Clinical Oncology*, **2013**, 31, 10001-10001	2.2	4

152	Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children's Oncology Group AALL1131.. *Journal of Clinical Oncology*, **2015**, 33, 10007-10007	2.2	4
151	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 289-289	2.2	4
150	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. *Cancer Research*, **2020**, 80, 5189-5202	10.1	4
149	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 794-802	6.1	4
148	Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. *Journal of Clinical Oncology*, **2021**, 39, 1540-1552	2.2	4
147	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. *Pediatric Blood and Cancer*, **2019**, 66, e27681	3	3
146	Refining prognosis in BCR-ABL1-positive ALL. *Blood*, **2014**, 123, 1626-7	2.2	3
145	State of the art discovery with tumor profiling in pediatric oncology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e601-7	7.1	3
144	Individualized therapy for childhood acute lymphoblastic leukemia. *Personalized Medicine*, **2005**, 2, 349-361	2.1	3
143	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. *Blood*, **2020**, 136, 20-21	2.2	3
142	Factors Influencing Survival after Relapse from Childhood ALL: A Children's Oncology Group Study.. *Blood*, **2006**, 108, 1855-1855	2.2	3
141	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. *Blood*, **2009**, 114, 907-907	2.2	3
140	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. *Blood*, **2011**, 118, 1440-1440	2.2	3
139	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. *Blood*, **2012**,	2.2	3
138	Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232. *Blood*, **2012**, 120, 665-665	2.2	3
137	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children's Oncology Group (COG) Study (AALL03N1). *Blood*, **2013**, 122, 59-59	2.2	3
136	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. *Blood*, **2013**, 122, 824-824	2.2	3
135	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 691-691	2.1	3

134	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. *Blood*, **2015**, 126, 82-82	2.2	3
133	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. *Blood*, **2016**, 128, 3965-3965	2.2	3
132	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. *Blood*, **2016**, 128, 451-451	2.2	3
131	The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children Oncology Group (COG) protocol AALL0433.. *Journal of Clinical Oncology*, **2014**, 32, 10014-10014	2.2	3
130	Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children Oncology Group (COG) trials.. *Journal of Clinical Oncology*, **2015**, 33, 10035-10035	2.2	3
129	Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG E. coli L-asparaginase): Results from Children Oncology Group (COG) study AALL07P4.. *Journal of Clinical Oncology*, **2016**, 34, 10508-10508	2.2	3
128	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions. *Cancers*, **2021**, 13,	6.6	3
127	Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. *British Journal of Haematology*, **2017**, 179, 843-846	4.5	2
126	Minimal Residual Disease(MRD) in Childhood Acute Lymphoblastic Leukemia(ALL) in Relapse. A Children Oncology Group (COG) Study.. *Blood*, **2004**, 104, 324-324	2.2	2
125	Nelarabine Can Be Safely Incorporated into an Intensive, Multiagent Chemotherapy Regimen for the Treatment of T-Cell Acute Lymphocytic Leukemia (ALL) in Children: A Report of the Children Oncology Group (COG) AALL00P2 Protocol for T-Cell Leukemia.. *Blood*, **2006**, 108, 1864-1864	2.2	2
124	Outcomes of Children with First Marrow Relapse: Results from Children Oncology Group (COG) Study AALL01P2.. *Blood*, **2006**, 108, 1871-1871	2.2	2
123	Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children Oncology Group (COG) Study.. *Blood*, **2006**, 108, 2585-2585	2.2	2
122	Genome-Wide Profiling of High-Risk Pediatric Acute Lymphoblastic Leukemia (ALL): The ALL Pilot Project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) Initiative.. *Blood*, **2007**, 110, 229-229	2.2	2
121	Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).. *Blood*	2.2	2
120	AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. *Blood*, **2009**, 114, 3076-3076	2.2	2
119	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. *Blood*, **2010**, 116, 2752-2752	2.2	2
118	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse a Children's Oncology Group (COG) Study (AALL03N1). *Blood*, **2012**, 120, 882-882	2.2	2
117	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. *Blood*, **2014**, 124, 791-791	2.2	2

116	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. *Blood*, **2016**, 128, 1086-1086	2.2	2
115	Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.. *Journal of Clinical Oncology*, **2012**, 30, 9548-9548	2.2	2
114	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children Oncology Group (COG) study AALL03N1.. *Journal of Clinical Oncology*, **2014**, 32, 10013-10013	2.2	2
113	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 649-649	2.2	2
112	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. *Blood* , **2021**, 137, 1550-1552	2.2	2
111	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.. *Cancer*, **2022**,	6.4	2
110	Reply to I.J. Cohen. *Journal of Clinical Oncology*, **2017**, 35, 3989-3991	2.2	1
109	The immunoglobulin gene repertoire to Haemophilus influenzae type b. *Annals of the New York Academy of Sciences*, **1995**, 764, 374-7	6.5	1
108	On target for advances in the treatment of childhood acute lymphoblastic leukemia. *Blood*, **2005**, 105, 438-439	2.2	1
107	A shuttle vector system for the investigation of immunoglobulin gene hypermutation: absence of enhanced mutability in intermediate B cell lines. *Molecular Immunology*, **1992**, 29, 1005-11	4.3	1
106	Selective right mainstem bronchus intubation as a treatment for persistent left pneumothorax in the newborn. *Clinical Pediatrics*, **1983**, 22, 450-2	1.2	1
105	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). *Blood*, **2018**, 132, 1000-1000	2.2	1
104	A Gene Expression Classifier for Improved Risk Classification and Outcome Prediction in Pediatric Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2005**, 106, 762-762	2.2	1
103	Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.. *Blood*, **2006**, 108, 283-283	2.2	1
102	Children with t(12;21)/TEL-AML1-Positive Acute Lymphoblastic Leukemia Exhibit a Distinct Germline Genomic Signature.. *Blood*, **2007**, 110, 760-760	2.2	1
101	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children Oncology Group (COG) Study AALL0031.. *Blood*, **2008**, 112, 911-911	2.2	1
100	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. *Blood*, **2009**, 114, 2389-2389	2.2	1
99	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. *Blood*, **2009**, 114, 320-320	2.2	1

98	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. *Blood*, **2010**, 116, 2757-2757	2.2	1
97	Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991. *Blood*, **2010**, 116, 497-497	2.2	1
96	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. *Blood*, **2011**, 118, 743-743	2.2	1
95	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. *Blood*, **2011**, 118, 837-837	2.2	1
94	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. *Blood*, **2012**, 120, 2529-2529	2.2	1
93	Inhibition Of The Wnt Pathway Leads To Improved Chemosensitivity In Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 1428-1428	2.2	1
92	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 60-60	2.2	1
91	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. *Blood*, **2014**, 124, 367-367	2.2	1
90	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *Blood*, **2015**, 126, 694-694	2.2	1
89	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). *Blood*, **2016**, 128, 758-758	2.2	1
88	Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Children's Oncology Group (COG) study AALL0331.. *Journal of Clinical Oncology*, **2013**, 31, 10002-10002	2.2	1
87	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) Studies AALL0331 and AALL0232.. *Journal of Clinical Oncology*, **2014**, 32, 10016-10016	2.2	1
86	Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children's Oncology Group (COG).. *Journal of Clinical Oncology*, **2019**, 37, 10005-10005	2.2	1
85	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. *Journal of Clinical Oncology*, **2020**, 38, 10510-10510	2.2	1
84	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. *Blood*, **2021**, 138, 211-211	2.2	1
83	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse.. *Blood*, **2006**, 108, 49-49	2.2	1
82	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 565-565	2.2	1
81	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. *Journal of Clinical Oncology*, **2020**, 38, 10509-10509	2.2	1

80	Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. *Blood*, **2008**, 112, 568-568	2.2	1
79	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. *Blood*, **2009**, 114, 2598-2598	2.2	1
78	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. *Blood*, **2011**, 118, 739-739	2.2	1
77	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 530-530	2.2	1
76	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children Oncology Group AALL1131.. *Journal of Clinical Oncology*, **2021**, 39, 10004-10004	2.2	1
75	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. *Blood Advances*, **2021**, 5, 2890-2900	7.8	1
74	The potential of precision medicine for childhood acute lymphoblastic leukemia: opportunities and challenges. *Expert Review of Precision Medicine and Drug Development*, **2018**, 3, 343-356	1.6	1
73	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. *Pediatric Blood and Cancer*, **2021**, 68, e29256	3	1
72	dMMR and thiopurines strand TP53 for ALL relapse.. *Nature Cancer*, **2021**, 2, 777-779	15.4	1
71	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. *Blood*, **2014**, 124, 132-132	2.2	0
70	NT5C2 As a Major Contributor to Thiopurine Resistance at ALL Relapse Via Multiple Mechanisms. *Blood*, **2015**, 126, 446-446	2.2	0
69	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. *Blood*, **2016**, 128, 455-455	2.2	0
68	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. *Blood*, **2008**, 112, 14-14	2.2	0
67	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. *Blood*, **2012**, 120, 877-877	2.2	0
66	Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia. *Blood*, **2013**, 122, 602-602	2.2	0
65	From Favorable Histology to Relapse: The Clonal Evolution of a Wilms Tumor. *Pediatric and Developmental Pathology*, **2020**, 23, 167-171	2.2	0
64	The ASPHO 2018 Distinguished Career Award goes to Dr. Michael P. Link. *Pediatric Blood and Cancer*, **2018**, 65 Suppl 1, e26987	3	
63	"When can I go home?"-seeking ways to lower the burden on patients and families. *Pediatric Blood and Cancer*, **2008**, 51, 318-9	3	

62	Eliminating a gold standard in childhood acute lymphoblastic leukemia?. *Pediatric Blood and Cancer*, **2006**, 47, 242-4	3
61	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. *Blood*, **2020**, 136, 38-39	2.2
60	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. *Blood*, **2021**, 138, 2382-2382	2.2
59	Non-Classical Monocyte Abundance Is an Independent Adverse Risk Factor for Relapse in Pediatric B-ALL. *Blood*, **2021**, 138, 1316-1316	2.2
58	Gene Expression Pathways That Distinguish Diagnosis and Relapse in Childhood Acute Lymphoblastic Leukemia.. *Blood*, **2005**, 106, 848-848	2.2
57	Gene Signatures Predictive of Outcome in Higher Risk Childhood Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2005**, 106, 1449-1449	2.2
56	Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children Oncology Group Study.. *Blood*, **2007**, 110, 1422-1422	2.2
55	Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children Oncology Group.. *Blood*, **2007**, 110, 758-758	2.2
54	Outcomes for B-Precursor Patients in Legacy Children Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children Oncology Group (COG) Report.. *Blood*, **2007**, 110, 847-847	2.2
53	Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Children Oncology Group Study.. *Blood*, **2007**, 110, 725-725	2.2
52	Expression Profiling Identifies Novel Genetic Subgroups with Distinct Clinical Features and Outcome in High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia (B-ALL). A Children Oncology Group Study.. *Blood*, **2007**, 110, 1430-1430	2.2
51	The NSD2 p.E1099K Mutation in Relapse Pediatric Acute Lymphoblastic Leukemia Is Linked to Mercaptopurine Resistance. *Blood*, **2018**, 132, 3962-3962	2.2
50	NSD2 Mutations in Pediatric ALL Leads to a Distinct Gene Expression Profile and Epigenetic Landscape That Is Cell Context Specific. *Blood*, **2018**, 132, 3905-3905	2.2
49	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. *Blood*, **2018**, 132, 659-659	2.2
48	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 612-612	2.2
47	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. *Blood*, **2014**, 124, 63-63	2.2
46	MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL. *Blood*, **2014**, 124, 789-789	2.2
45	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 792-792	2.2

44	Resource Utilization and Cost Analysis By Treatment Arm on the Children Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children Oncology Group. *Blood*, **2014**, 124, 210-210	2.2
43	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children Oncology Group (COG) Study (AALL03N1). *Blood*, **2014**, 124, 369-369	2.2
42	Neurocognitive function of children treated for high-risk B-acute lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus high-dose methotrexate (HDMTX): A report from the Children Oncology Group (COG).. *Journal of Clinical Oncology*, **2015**, 33, 10002-10002	2.2
41	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. *Blood*, **2016**, 128, 4083-4083	2.2
40	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 2906-2906	2.2
39	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 759-759	2.2
38	Using Whole Exome Sequencing in Pediatric Acute Lymphoblastic Leukemia Germline, Diagnosis, and Relapse Trios to Discover Novel Relapse Enriched Mutations for Clonal Backtracking By Ddpcr. *Blood*, **2016**, 128, 4085-4085	2.2
37	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 907-907	2.2
36	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. *Blood*, **2016**, 128, 1739-1739	2.2
35	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. *Journal of Clinical Oncology*, **2017**, 35, 10514-10514	2.2
34	Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children Oncology Group Study 1991. *Blood*, **2008**, 112, 701-701	2.2
33	Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse.. *Blood*, **2008**, 112, 3345-3345	2.2
32	Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients.. *Blood*, **2008**, 112, 1203-1203	2.2
31	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children Oncology Group (COG) Study.. *Blood*, **2008**, 112, 2256-2256	2.2
30	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children Oncology Group Trials.. *Blood*, **2008**, 112, 1514-1514	2.2
29	Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2008**, 112, 427-427	2.2
28	Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children Oncology Group (COG).. *Blood*, **2008**, 112, 917-917	2.2
27	Up-Regulation of Genes Involved in Folate Metabolism Characterize Late but Not Early Relapse in Childhood Acute Lymphoblastic Leukemia.. *Blood*, **2009**, 114, 1733-1733	2.2

26	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. *Blood*, **2009**, 114, 2606-2606	2.2
25	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. *Blood*, **2009**, 114, 2634-2634	2.2
24	Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. *Blood*, **2010**, 116, 414-414	2.2
23	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *Blood*, **2010**, 116, 8-8	2.2
22	Administration of Erwinia Asparaginase (Erwinase) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). *Blood*, **2010**, 116, 2134-2134	2.2
21	Vorinostat Reverses Relapse-Specific Drug Resistance Gene Expression Signatures In Childhood Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2010**, 116, 3630-3630	2.2
20	Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 866-866	2.2
19	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (90 Days): A Children's Oncology Group Study. *Blood*, **2010**, 116, 412-412	2.2
18	High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL) Identifies Relapse Specific Mutations and Expression. *Blood*, **2010**, 116, 3233-3233	2.2
17	Epigenetic Modulation Leads to Re-Expression of Relapse Specific Silenced Genes and Induces Chemosensitivity in Childhood Acute Lymphoblastic Leukemia (ALL),. *Blood*, **2011**, 118, 3455-3455	2.2
16	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children Oncology Group study AALL0232.. *Journal of Clinical Oncology*, **2012**, 30, CRA9508-CRA9508	2.2
15	Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.. *Journal of Clinical Oncology*, **2012**, 30, 9543-9543	2.2
14	Relapse-specific mutations in cytosolic 5 hucleotidase II in childhood acute lymphoblastic leukemia.. *Journal of Clinical Oncology*, **2012**, 30, 9507-9507	2.2
13	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. *Blood*, **2012**, 120, 1300-1300	2.2
12	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.. *Blood*, **2012**, 120, 2563-2563	2.2
11	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. *Blood*, **2012**, 120, 776-776	2.2
10	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. *Blood*, **2012**, 120, 291-291	2.2
9	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. *Blood*, **2012**, 120, 2505-2505	2.2

8	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.. *Blood*, **2012**, 120, 2565-2565	2.2
7	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. *Blood*, **2012**, 120, 528-528	2.2
6	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 3868-3868	2.2
5	Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway In Glucocorticoid Resistance In Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 1296-1296	2.2
4	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. *Blood*, **2013**, 122, 229-229	2.2
3	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children Oncology Group.. *Journal of Clinical Oncology*, **2021**, 39, 10003-10003	2.2
2	Reply to A. K. Agrawal et al. *Journal of Clinical Oncology*, **2021**, 39, 695-696	2.2
1	The new reality is virtual.. *Pediatric Blood and Cancer*, **2022**, e29774	3